Significance of IgG for the activity of factor XII measured in human plasma

References

• Fossum S, Hoem NO, Johannesen S, Korpberget M, Nylund E, Sandem S, et al. Contact factors in plasma from women on oral contraception: significance of factor XI for the measured activity of factor XII. Thromb Res 1994; 74: 477–85
   PubMedGoogle Scholar
• Briseid K, Hoem NO, Johannesen S, Haug K. Amidolytic assay of factor XI in human plasma: sigmficance of kallikrein for the activity measured. Thromb Res 1995; 78: 239–50
   PubMed Web of Science ®Google Scholar
• Griffin JH, Cochrane CG. Human factor XII (Hageman factor). Methods Enzymol 1976; 45: 56–65
   PubMedGoogle Scholar
• Saito H, Ratnoff OD, Pensky J. Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 1976; 88: 506–14
   PubMed Web of Science ®Google Scholar
• Saito H, Scially SJ. Isolation and properties of an abnormal Hageman factor (factor XII) molecule in a cross-reacting material-positive Hageman trait plasma. J Clin Invest 1981; 68: 1028–35
   PubMedGoogle Scholar
• Wuillemin WA, Furlan M, Huber I, Lämmle B. Purified factor XII has a higher specific activity than the parent molecule in plasma. Thromb Haemost 1991; 65: 169–73
   PubMedGoogle Scholar
• Hoem NO, Johannesen S, Hauge G, Rud AC, Sandem S, Briseid K. Contact activation factors in plasma from women using oral contraceptives: increased levels of factor XII, kinin-free high molecular weight kininogen and acetone-activated kallikrein. Thromb Res 1991; 64: 427–34
   PubMed Web of Science ®Google Scholar
• Laake K, Vennerød AM. Determination of factor XII in human plasma with arginine proesterase (prekallikrein). I Preparation and properties of the substrate. Thromb Res 1973; 2: 394–407
   Google Scholar
• Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235–54
   PubMedGoogle Scholar
• Briseid K, Hoem NO, Johannesen S, Marthinsen K. Functional correlation between kallikrein and factor XII activated in human plasma. Thromb Res 1990; 57: 945–56
   PubMedGoogle Scholar
• Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia.In vivouse of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61–8
   PubMed Web of Science ®Google Scholar
• Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an hapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 1987; 262: 10140–5
   PubMed Web of Science ®Google Scholar
• Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res 1980; 20: 149–62
   PubMedGoogle Scholar
• Chong GL, Reeck GR. Interaction of trypsin, β-factor XIIa, and plasma kallikrein with a trypsin inhibitor isolated from barley seeds. a comparison with the corn inhibitor of activated Hageman factor. Thromb Res 1987; 48: 211–21
   PubMedGoogle Scholar
• Tans G, Janssen-Claessen T, Rosing J, Griffin JH. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. Eur J Biochem 1987; 164: 637–42
   PubMedGoogle Scholar
• Castro O, Farber LR, Clyne LP. Circulating anticoagulants against factors IX and XI in systemic lupus erythematosus. AM Intern Med 1972; 77: 543–48
   Google Scholar
• Åberg H, Nilsson IM. Recurrent thrombosis in a young woman with a circulating anticoagulant directed against factors XI and XII. Acta Med Scand 1972; 192: 419–25
   PubMedGoogle Scholar
• Cronberg S, Nilsson IM. Circulating anticoagulant against factors XI and XII together with massive spontaneous platelet aggregation. Scand J Haematol 1973; 10: 309–14
   PubMedGoogle Scholar
• Stem DM, Nossel HL, Owen J. Acquired antibody to factor XI in a patient with congenital factor XI deficiency. J Clin Invest 1982; 69: 1270–6
   PubMedGoogle Scholar
• Poon M-C, Saito H, Koopman WJ. A unique precipitating autoantibody against plasma throm-boplastin antecedent associated with multiple apparent plasma clotting factor deficiencies in a patient with systemic lupus erythematosus. Blood 1984; 63: 1309–17
   PubMedGoogle Scholar
• Chediak J, Madej-Zevh P, Ratnoff OD. Studies on circulating anticoagulant inhibiting factor XI in a patient with congenital deficiency and carcinoma of the prostate. Brit J Haematol 1986; 63: 123–33
   PubMedGoogle Scholar
• De La Cadena RA, Baglia FA, Johnson CA, Wenk RE, Amernick R, Walsh PN, et al. Naturally occuring antibodies against two distinct functional domains in the heavy chain of FXU FXIa. Blood 1988; 72: 1748–54
   PubMedGoogle Scholar
• Tans G, Rosing J, Berretini M, Lämmle B, Griffin JH. Autoactivation of human plasma prekallikrein. J Biol Chem 1987; 262: 11308–14
   PubMedGoogle Scholar
• Kaplan AP, Austen KF. A pre-albumin activator of prekallikrein. J Immunol 1970; 105: 802–11
   PubMedGoogle Scholar
• Kaplan AP, Austen KF. A pre-albumin activator of prekallikrein. II Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exper Med 1971; 133: 696–712
   PubMed Web of Science ®Google Scholar
• Bagdasarian A, Talamo C, Colman RW. Isolation of high molecular weight activators of human plasma prekallikrein. J Biol Chem 1973; 248: 3456–63
   PubMed Web of Science ®Google Scholar
• Bagdasarian A, Lahiri B, Colman RW. Origin of the high molecular weight activator of prekallikrein. J Biol Chem 1973; 248: 7742–7
   PubMedGoogle Scholar
• Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982; 257: 1779–82
   PubMed Web of Science ®Google Scholar